Literature DB >> 17240494

The antigenicity of a Plasmodium vivax reticulocyte binding protein-1 (PvRBP1) recombinant fragment in humans and its immunogenicity and protection studies in Aotus monkeys.

Jose Rojas Caraballo1, Gabriela Delgado, Raul Rodriguez, Manuel A Patarroyo.   

Abstract

Plasmodium vivax merozoites have been found to specifically invade immature red blood cells (reticulocytes) and this preference has been associated with two proteins named reticulocyte binding protein-1 and protein-2 (PvRBP1 and PvRBP2). Previous reticulocyte binding assays using 15-mer synthetic peptides spanning the entire PvRBP1 sequence have shown that 25 out of the 195 peptides synthesised (grouped into 4 different regions) displayed high affinity binding to reticulocytes. The PvRBP1 region III (amino acids 1998-2348), encompassing 9 of the previously described high-affinity reticulocyte binding peptides, was expressed as a recombinant protein in the present study. This protein has been shown to be antigenic in humans and it has also been able to induce good humoral and cellular immune responses in Aotus nancymaae monkeys. Despite its high immunogenicity, no protective efficacy was observed in the immunised animals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17240494     DOI: 10.1016/j.vaccine.2006.12.041

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Plasmodium vivax DBP binding to Aotus nancymaae erythrocytes is Duffy antigen dependent.

Authors:  A M McHenry; J W Barnwell; J H Adams
Journal:  J Parasitol       Date:  2010-02       Impact factor: 1.276

2.  Identification and Immunological Characterization of the Ligand Domain of Plasmodium vivax Reticulocyte Binding Protein 1a.

Authors:  Francis B Ntumngia; Richard Thomson-Luque; Sandra Galusic; Gabriel Frato; Sarah Frischmann; David S Peabody; Bryce Chackerian; Marcelo U Ferreira; Christopher L King; John H Adams
Journal:  J Infect Dis       Date:  2018-08-24       Impact factor: 5.226

Review 3.  Progress towards the development of a P. vivax vaccine.

Authors:  Sai Lata De; Francis B Ntumngia; Justin Nicholas; John H Adams
Journal:  Expert Rev Vaccines       Date:  2021-03-04       Impact factor: 5.217

4.  Genetic diversity in new members of the reticulocyte binding protein family in Thai Plasmodium vivax isolates.

Authors:  Varakorn Kosaisavee; Usa Lek-Uthai; Rossarin Suwanarusk; Anne Charlotte Grüner; Bruce Russell; Francois Nosten; Laurent Rénia; Georges Snounou
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

5.  Identification of a reticulocyte-specific binding domain of Plasmodium vivax reticulocyte-binding protein 1 that is homologous to the PfRh4 erythrocyte-binding domain.

Authors:  Jin-Hee Han; Seong-Kyun Lee; Bo Wang; Fauzi Muh; Myat Htut Nyunt; Sunghun Na; Kwon-Soo Ha; Seok-Ho Hong; Won Sun Park; Jetsumon Sattabongkot; Takafumi Tsuboi; Eun-Taek Han
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

Review 6.  What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates?

Authors:  Carolina López; Yoelis Yepes-Pérez; Natalia Hincapié-Escobar; Diana Díaz-Arévalo; Manuel A Patarroyo
Journal:  Front Immunol       Date:  2017-02-13       Impact factor: 7.561

Review 7.  Plasmodium vivax Reticulocyte Binding Proteins for invasion into reticulocytes.

Authors:  Li-Jin Chan; Melanie H Dietrich; Wang Nguitragool; Wai-Hong Tham
Journal:  Cell Microbiol       Date:  2019-09-08       Impact factor: 4.115

8.  Plasmodium vivax Reticulocyte Binding Proteins Are Key Targets of Naturally Acquired Immunity in Young Papua New Guinean Children.

Authors:  Camila T França; Wen-Qiang He; Jakub Gruszczyk; Nicholas T Y Lim; Enmoore Lin; Benson Kiniboro; Peter M Siba; Wai-Hong Tham; Ivo Mueller
Journal:  PLoS Negl Trop Dis       Date:  2016-09-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.